Get started
Author

Jorma Sormunen

Observed names: J. Sormunen, JORMA SORMUNEN, Jorma S. Sormunen, Jorma T.J Sormunen, Jorma Tauno Juhani Sormunen, Sormunen, Jorma
ORCID: 0000-0002-1992-1251
Observed ORCID: 0000-0002-1992-1251
OpenAlex ID: A5024539974
Benzene exposure at workplace and risk of colorectal cancer in four Nordic countries
2018 · Madar Talibov, Jorma Sormunen, et al. · Cancer Epidemiology · 52
PDF
Lifetime physical activity and cancer incidence—A cohort study of male former elite athletes in Finland
2013 · Jorma Sormunen, Heli M. Bäckmand, et al. · Journal of science and medicine in sport · 42
PDF
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
2025 · Matthew Stephen Block, James Hugo Armstrong Clubb, et al. · Nature Communications · 39
PDF
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al. · Clinical Cancer Research · 36
PDF
Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
2022 · Anniina Hyväkkä, Okko‐Sakari Kääriäinen, et al. · Cancer Medicine · 23
PDF
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
2025 · Santeri A Pakola, James H A Clubb, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Workplace Diesel Exhausts and Gasoline Exposure and Risk of Colorectal Cancer in Four Nordic Countries
2019 · Madar Talibov, Jorma Sormunen, et al. · Safety and Health at Work · 9
PDF
Perceived physical strain at work and incidence of colorectal cancer: A nested case–control study
2016 · Jorma Sormunen, Madar Talibov, et al. · Cancer Epidemiology · 8
Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial
2025 · Lauri Rantaniemi, Ilkka Jussila, et al. · Scandinavian Journal of Medicine and Science in Sports · 6
Perceived Physical Strain at Work and Incidence of Prostate Cancer – a Case-Control Study in Sweden and Finland
2018 · Jorma Sormunen, Madar Talibov, et al. · Europe PMC (PubMed Central) · 5
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial
2022 · Miikka Lehtonen, Jorma Sormunen, et al. · Acta Oncologica · 4
Cohort profile: a nationwide cohort of Finnish military recruits born in 1958 to study the impact of lifestyle factors in early adulthood on disease outcomes
2017 · Jorma Sormunen, Melina Arnold, et al. · BMJ Open · 4
PDF
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors
2026 · Elise Jirovec, Katriina J. Jalkanen, et al. · Molecular Therapy · 2
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
2023 · Joao Santos, Katriina Peltola, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Experiences of exercise and its significance for the quality of life among patients with advanced cancer – A qualitative study
2025 · Essi Nikkinen, Eeva Harju, et al. · European Journal of Oncology Nursing · 1
Abstract CT139: Immunological activity of oncolytic adenovirus encoding TNFα and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients
2024 · James H. Clubb, Matthew S. Block, et al. · Cancer Research · 1
Measuring oncological value of exercise and statin: Can we improve the prognosis of patients with cancer and change the microenvironment in different tumor types with exercise and statins (MOVES study)?
2024 · Jorma T.J Sormunen, Annastiina Hakulinen, et al. · Journal of Clinical Oncology · 1
PDF
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
2023 · Joao Santos, Inge Svane, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
2021 · MIIKKA LEHTONEN, JORMA SORMUNEN, et al. · Anticancer Research · 1
PDF
Effects of physical condition and body composition on cancer risk in a nationwide cohort of 31,158 men from Finland.
2017 · Jorma Tauno Juhani Sormunen, Melina Arnold, et al. · Journal of Clinical Oncology · 1
Congress presentation: IMS 2026 Identification of Vasomotor Symptom Prevalence and Severity in Women with Hormone Receptor Positive Breast Cancer using Large Language Model Based Data Extraction from Routine Electronic Health Records
2026 · Michelle Jacobson, Joehl Nguyen, et al. · Bayer AG
Congress poster: ESMO Breast Cancer 2026 Pharmacokinetics, compliance, and oestradiol levels in women with breast cancer receiving elinzanetant for the treatment of endocrine therapy-associated vasomotor symptoms
2026 · Cardoso, Fatima, Block, Michael, et al. · Bayer AG
604P Pharmacokinetics, compliance and estradiol levels in women with breast cancer receiving elinzanetant for the treatment of endocrine therapy-associated vasomotor symptoms
2026 · F. Cardoso, M. Block, et al. · ESMO Open
PDF
Measuring the oncological value of exercise and statins (MOVES): Changing the tumour microenvironment with exercise and statins — an exploratory pilot trial
2026 · Teemu Murtola, Annastiina Hakulinen, et al. · Research Square
PDF
1203P Clinical correlations and long-term survival in PROTA: Platinum-resistant or refractory ovarian cancer treated with an oncolytic adenovirus encoding TNF and IL2 in combination with pembrolizumab
2025 · N. Ojala, J. Clubb, et al. · Annals of Oncology
Works count: 49
Citation count: 249
H-index: 8
I10-index: 6
Year
Topic
Type